Are PG's Beauty and Health Units Driving the Next Leg of Growth?

Procter & Gamble is focusing on its health and beauty segments to drive growth, with management citing a $5 billion opportunity in power oral care; Q3 2025 saw Beauty organic sales increase 2% while Health Care rose 4%. The company is investing in innovation and brand equity amid near-term volatility, specifically targeting premium offerings in skincare and strengthening its department store presence; however, PG's shares have underperformed the industry year-to-date, and its forward P/E ratio is above the industry average.

Analysis

Procter & Gamble (PG) is strategically emphasizing its Health and Beauty segments as primary growth engines, highlighted by a significant $5 billion opportunity identified in the power oral care market through innovations like the iO2 toothbrush. In third-quarter fiscal 2025, the Beauty segment, contributing 18% to sales, saw a 2% year-over-year organic sales increase, while the Health Care segment, accounting for 15% of sales, grew 4% organically. Performance within these segments was mixed: Personal Care and Personal Health Care delivered high single-digit organic sales growth, driven by innovation and volume. Conversely, Hair Care organic sales were flat due to lower volumes in Greater China offsetting price increases, and Skin Care organic sales declined by low single digits. Despite these targeted growth initiatives and management's commitment to long-term brand equity and innovation, PG's shares have underperformed, declining 3.7% year-to-date compared to the industry's 0.7% dip. The company trades at a forward price-to-earnings ratio of 22.94X, above the industry average of 20.46X. While Zacks Consensus Estimates project EPS growth of 2.9% for fiscal 2025 and 3.6% for fiscal 2026 (with the FY26 estimate recently revised upwards), the stock currently holds a Zacks Rank #4 (Sell). Comparatively, competitors like Clorox (CLX) are showing strong momentum, with its Health and Wellness segment delivering 3% net sales growth in Q3 FY25 and an anticipated 6% organic sales growth for Q4.

Key Decisions for Investors

• Investors should critically evaluate Procter & Gamble's strategic initiatives in health and beauty, including the substantial power oral care opportunity, in conjunction with its current premium valuation (22.94X P/E vs. 20.46X industry) and recent share price underperformance (-3.7% YTD).
• Vigilant monitoring of the Beauty segment's performance is advised, particularly focusing on volume recovery in Greater China for Hair Care and a turnaround in the Skin Care category, given their mixed results in Q3 fiscal 2025.
• The Zacks Rank #4 (Sell) designation, alongside the stock's relative underperformance against the industry and peers like Clorox which projects stronger near-term organic growth, suggests a cautious investment approach may be warranted, potentially involving a re-evaluation of exposure within the consumer staples sector.